Oscar Health price target raised to $3.90 from $3.25 at BofA

BofA raised the firm’s price target on Oscar Health to $3.90 from $3.25 and keeps an Underperform rating on the shares. Oscar’s "growth story got a boost in visibility" after founder-CEO Mario Schlosser announced he would cede control to industry veteran Mark Bertolini, said the firm. However, BofA maintains its Underperform rating as it awaits more concrete milestones in the turnaround that will now be led by the former CEO of Aetna.